Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial

This is a secondary safety and health-related quality-of-life analysis of the phase 3 ALINA trial (257 patients: 130 assigned alectinib, 127 chemotherapy after resection of ALK-positive non-small-cell lung cancer), not the efficacy report — the disease-free survival result was published previously. Alectinib's safety profile was manageable: serious adverse events occurred in 2 of 128 patients (2%) versus 8 of 120 (7%) on chemotherapy, and discontinuations due to adverse events in 7 (5%) versus 15 (13%). Quality of life improved and was maintained over 2 years of active treatment (at week 96, mean Mental Component Summary 49.9 [SD 10.4], Physical Component Summary 48.8 [SD 7.2]).